ATE85810T1 - Oxidationsbestaendige il-2-muteine und ihre herstellung, diese muteine enthaltende zusammensetzungen, solche muteine kodierende dns- sequenzen und expressionsvektoren und korrespondierende transformierte wirtzellen. - Google Patents

Oxidationsbestaendige il-2-muteine und ihre herstellung, diese muteine enthaltende zusammensetzungen, solche muteine kodierende dns- sequenzen und expressionsvektoren und korrespondierende transformierte wirtzellen.

Info

Publication number
ATE85810T1
ATE85810T1 AT86200766T AT86200766T ATE85810T1 AT E85810 T1 ATE85810 T1 AT E85810T1 AT 86200766 T AT86200766 T AT 86200766T AT 86200766 T AT86200766 T AT 86200766T AT E85810 T1 ATE85810 T1 AT E85810T1
Authority
AT
Austria
Prior art keywords
muteins
oxidation
correspondent
resistant
production
Prior art date
Application number
AT86200766T
Other languages
English (en)
Inventor
Kirston Edward Koths
Robert Forgan Halenbeck
Michael Allan Innis
Original Assignee
Cetus Oncology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Oncology Corp filed Critical Cetus Oncology Corp
Application granted granted Critical
Publication of ATE85810T1 publication Critical patent/ATE85810T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Peptides Or Proteins (AREA)
  • Dental Preparations (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
AT86200766T 1985-01-18 1986-01-17 Oxidationsbestaendige il-2-muteine und ihre herstellung, diese muteine enthaltende zusammensetzungen, solche muteine kodierende dns- sequenzen und expressionsvektoren und korrespondierende transformierte wirtzellen. ATE85810T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69259685A 1985-01-18 1985-01-18
US81065685A 1985-12-17 1985-12-17

Publications (1)

Publication Number Publication Date
ATE85810T1 true ATE85810T1 (de) 1993-03-15

Family

ID=36846757

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86200766T ATE85810T1 (de) 1985-01-18 1986-01-17 Oxidationsbestaendige il-2-muteine und ihre herstellung, diese muteine enthaltende zusammensetzungen, solche muteine kodierende dns- sequenzen und expressionsvektoren und korrespondierende transformierte wirtzellen.

Country Status (7)

Country Link
EP (1) EP0200280B1 (de)
JP (1) JP2595206B2 (de)
AT (1) ATE85810T1 (de)
AU (2) AU5245186A (de)
CA (1) CA1340265C (de)
DE (1) DE3687763T2 (de)
NZ (1) NZ214854A (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107465A (en) * 1984-12-21 2000-08-22 Otsuka Pharmaceutical Co., Ltd. IL-1β and derivatives thereof and drugs
US5342614A (en) * 1984-12-21 1994-08-30 Otsuka Pharmaceutical Co., Ltd. Method of treating arthritus or inflammation with IL-1β or derivatives thereof
CA1340265C (en) * 1985-01-18 1998-12-15 Kirston E. Koths Oxidation resistant muteins
AU595864B2 (en) * 1986-03-14 1990-04-12 Otsuka Pharmaceutical Co., Ltd. Il-1 alpha derivatives and drugs
US4835260A (en) * 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
AU627477B2 (en) * 1988-07-05 1992-08-27 Amgen, Inc. Interleukin ii analogs
WO2001000797A1 (en) * 1999-06-29 2001-01-04 National Institute Of Advances Industrial Science And Technology Sulfur atom-free enzyme proteins
ATE447412T1 (de) 2003-11-04 2009-11-15 Novartis Vaccines & Diagnostic Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren
CA2712432C (en) * 2008-01-29 2018-09-25 Ablynx N.V. Methods to stabilize single variable domains
DK2683395T3 (en) 2011-03-11 2018-11-19 Hopitaux Paris Assist Publique USE OF LOW DOSAGE IL-2 FOR TREATMENT OF TYPE 1 DIABETES
EP3013355B1 (de) 2013-06-25 2019-08-07 ICM - Institut du Cerveau et da la Moelle Epinière Il-2 zur verwendung in der behandlung von alzheimer-krankheit und verwandten erkrankungen
EP2918285A1 (de) 2014-03-11 2015-09-16 Université Pierre et Marie Curie (Paris 6) Interleukin-2 zur Behandlung einer Lebensmittelallergie
RU2573933C1 (ru) * 2014-08-21 2016-01-27 Дафот Энтерпрайсис Лимитед Пептид для лечения сахарного диабета 2-го типа и его осложнений
ES2982752T3 (es) 2015-10-22 2024-10-17 Iltoo Pharma Composiciones farmacéuticas de il-2
EP3475413B1 (de) 2016-06-22 2024-02-14 David Klatzmann Genetisch modifizierte t-lymphozyten
CA3055200A1 (en) 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Compositions and methods for immunotherapy
EP3596108A4 (de) 2017-03-15 2020-12-23 Pandion Operations, Inc. Gezielte immuntoleranz
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3752178A1 (de) 2018-02-16 2020-12-23 Iltoo Pharma Verwendung von interleukin 2 zur behandlung des sjögren-syndroms
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
US12403181B2 (en) 2018-08-13 2025-09-02 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
US12352765B2 (en) 2018-11-15 2025-07-08 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods of prognosis and classification for preeclampsia
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
BR112022011414A2 (pt) 2019-12-12 2022-08-30 Iltoo Pharma Construção quimérica, proteína homodimérica, proteína heterodimérica, ácido nucleico, vetor, célula hospedeira, métodos para produzir uma proteína dimérica e para produzir uma proteína heterodimérica
EP4107187A4 (de) 2020-02-21 2024-07-03 Pandion Operations, Inc. Gewebegezielte immuntoleranz mit einem cd39-effektor
JP7840267B2 (ja) 2020-03-06 2026-04-03 サントル、オスピタリエ、ユニヴェルシテール、ド、ニーム 筋萎縮性側索硬化症の治療のための低用量ヒトインターロイキン-2
CN118414160A (zh) 2021-10-06 2024-07-30 艾尔图制药公司 对发炎组织具有靶向特异性的白介素2嵌合构建体
EP4587043A1 (de) 2022-09-12 2025-07-23 Institut National de la Santé et de la Recherche Médicale (INSERM) Interleukin-2 zur verwendung bei der behandlung von autismusspektrumsstörungen
EP4630035A1 (de) 2022-12-05 2025-10-15 Centre Hospitalier Universitaire de Nimes Niedrigdosiertes humanes interleukin-2 zur behandlung von amyotropher lateralsklerose in einer untergruppe von patienten
WO2025032158A1 (en) 2023-08-08 2025-02-13 Institut National de la Santé et de la Recherche Médicale Method to treat tauopathies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2544348C3 (de) * 1975-10-03 1979-12-13 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen L-Leucin-13-Motilin, Verfahren zu dessen Herstellung und dasselbe enthaltendes Mittel
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
JPS605600B2 (ja) * 1982-10-25 1985-02-12 工業技術院長 新規なポリペプチド
AU574064B2 (en) * 1983-03-07 1988-06-30 F. Hoffmann-La Roche Ag Growth hormone releasing factor analogues
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
NZ208612A (en) 1983-06-24 1991-09-25 Genentech Inc Method of producing "procaryotic carbonyl hydrolases" containing predetermined, site specific mutations
WO1985000817A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
US4530787A (en) 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
DE3419995A1 (de) * 1984-05-29 1985-12-05 Hoechst Ag, 6230 Frankfurt Gentechnologisches verfahren zur herstellung von human-interleukin-2 und mittel zur durchfuehrung dieses verfahrens
JPS6124599A (ja) * 1984-07-11 1986-02-03 Kyowa Hakko Kogyo Co Ltd 新規ヒトインタ−フエロン−rポリペプチド誘導体
CA1340265C (en) * 1985-01-18 1998-12-15 Kirston E. Koths Oxidation resistant muteins

Also Published As

Publication number Publication date
JP2595206B2 (ja) 1997-04-02
CA1340265C (en) 1998-12-15
NZ214854A (en) 1989-07-27
AU6484686A (en) 1987-02-05
EP0200280A2 (de) 1986-11-05
AU5245186A (en) 1986-07-31
DE3687763D1 (de) 1993-03-25
DE3687763T2 (de) 1993-06-09
EP0200280A3 (en) 1988-08-24
JPS61224985A (ja) 1986-10-06
EP0200280B1 (de) 1993-02-17
AU585084B2 (en) 1989-06-08

Similar Documents

Publication Publication Date Title
ATE85810T1 (de) Oxidationsbestaendige il-2-muteine und ihre herstellung, diese muteine enthaltende zusammensetzungen, solche muteine kodierende dns- sequenzen und expressionsvektoren und korrespondierende transformierte wirtzellen.
DE3380598D1 (en) Cysteine-depleted muteins of interferon-beta, their preparation, formulations containing them, and structural genes, vectors and organisms, and their production, suitable for use in the preparation of said muteins
DE3584579D1 (de) Herstellung von polypeptiden mit human-gammainterferon-aktivitaet.
ATE246246T1 (de) Herstellung von hämoglobin und analogen davon in nicht-erythrozytzellen
GR3021198T3 (en) Interleukin-4 protein having bcgf and tcgf activity on human cells (human interleukin-4)
EP0458959A4 (en) Novel platelet-derived growth factor b chain analogs and method for homogeneous production thereof
ATE123813T1 (de) Tierische interferone, verfahren bei deren herstellung, dieselben enthaltende zusammensetzungen, kodierende dns-sequenzen hierfür und diese sequenzen enthaltende expressionsvektoren und dadurch transformierte zellen.
DE3750915D1 (de) Für Antitumor-Polypeptide kodierende DNS, die Polypeptide und diese Polypeptide enthaltenden Antitumor-Wirkstoffe.
DE3751269D1 (de) Expression des biologisch aktiven Faktors XIII.
ATE72582T1 (de) Oxidationsresistente muteine von beta-interferon, deren herstellung und diese muteine enthaltende praeparate.
IL75963A (en) Omega interferon polypeptides of type 1,n-glycosylated derivatives thereof with omega interferon activity,polynucleotide sequences encoding the omega interferon polypeptides,methods for the preparation of the polypeptides and pharmaceutical compositions containing them
IL80562A0 (en) Recombinant human lysozyme,its preparation by recombinant dna technology and pharmaceutical compositions containing it
ES2081817T3 (es) Polipeptido con secuencias principales repetidas que se fijan en la celula.
EP0249096B1 (de) Reninhemmende Aminosäurederivate.
DE3574145D1 (en) Novel, distinct family of human leukocyte interferons, compositions containing them, methods for their production, and dna and transfected hosts therefor
SE8502430D0 (sv) A cdna molecule coding for the expression of an interferon alfa type polypeptide, a bacterial or cellular host transformed with such molecule and a polypeptide showing interferon activity prepared by such host
DE68918399D1 (de) Lymphokine, DNS-Sequenzen, die diese Lymphokine kodieren, und sie enthaltende pharmazeutische Zusammensetzungen.
ATE152127T1 (de) Muteine des menschlichen parathormons und ihre herstellung
ATE102997T1 (de) Thymosin und tnf-kodierende dna.
BG60657B2 (en) Human recombinant interleukin-2 muteins

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
EELA Cancelled due to lapse of time